Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -25.60% is 30% below its 5-year average of -19.71%, near the low end of its 5-year range (-43.04%–40.73%).
23.76% above its 12-month average of -33.58%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.23%.
RETURN ON ASSETS (ROA)
-25.60%
RETURN ON ASSETS (ROA) AVG TTM
-33.58%
RETURN ON ASSETS (ROA) AVG 3Y
-30.56%
RETURN ON ASSETS (ROA) AVG 5Y
-19.71%
RETURN ON ASSETS (ROA) AVG 10Y
-25.72%
RETURN ON ASSETS (ROA) AVG 15Y
-32.94%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+23.76%
CURRENT VS 3Y AVG
+16.23%
CURRENT VS 5Y AVG
-29.91%
CURRENT VS 10Y AVG
+0.46%
CURRENT VS 15Y AVG
+22.27%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+20.66%
vs the sector median at left
uniQure N.V.
Market Cap
$1.60B
Return on Assets (ROA)
-25.60%
TTM Avg
-33.58%
3Y Avg
-30.56%
5Y Avg
-19.71%
Market Cap
$1.61B
Return on Assets (ROA)
-44.90%
TTM Avg
-37.58%
3Y Avg
-38.70%
5Y Avg
-36.23%
Market Cap
$1.61B
Return on Assets (ROA)
-4.28%
TTM Avg
-11.96%
3Y Avg
-5.19%
5Y Avg
-5.19%
Market Cap
$1.59B
Return on Assets (ROA)
-43.15%
TTM Avg
-37.60%
3Y Avg
-124.49%
5Y Avg
-99.59%
Market Cap
$1.61B
Return on Assets (ROA)
1.96%
TTM Avg
0.34%
3Y Avg
0.01%
5Y Avg
0.90%
Market Cap
$1.62B
Return on Assets (ROA)
-13.91%
TTM Avg
-19.51%
3Y Avg
-22.81%
5Y Avg
-24.34%
Market Cap
$1.63B
Return on Assets (ROA)
7.08%
TTM Avg
2.00%
3Y Avg
-0.05%
5Y Avg
-1.77%
Market Cap
$1.57B
Return on Assets (ROA)
-52.77%
TTM Avg
-17.21%
3Y Avg
-29.94%
5Y Avg
-28.87%
Market Cap
$1.54B
Return on Assets (ROA)
-31.37%
TTM Avg
-48.93%
3Y Avg
-40.51%
5Y Avg
-30.14%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| uniQure N.V. (QURE) | $1.60B | -25.60% | -33.58% | -30.56% | -19.71% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | -44.90% | -37.58% | -38.70% | -36.23% |
| Septerna Inc (SEPN)vs › | $1.61B | -4.28% | -11.96% | -5.19% | -5.19% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -43.15% | -37.60% | -124.49% | -99.59% |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 1.96% | 0.34% | 0.01% | 0.90% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | -13.91% | -19.51% | -22.81% | -24.34% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 7.08% | 2.00% | -0.05% | -1.77% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -52.77% | -17.21% | -29.94% | -28.87% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -31.37% | -48.93% | -40.51% | -30.14% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 20.98% | 9.19% | 12.55% | 16.89% |
ROA
-25.6%
ROE
-77.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -24.12% |
| 2024-12-31 | -43.04% |
| 2023-12-31 | -37.09% |
| 2022-12-31 | -17.99% |
| 2021-12-31 | 40.73% |
| 2020-12-31 | -36.73% |
| 2019-12-31 | -27.68% |
| 2018-12-31 | -30.41% |
| 2017-12-31 | -38.49% |
| 2016-12-31 | -38.56% |
| 2015-12-31 | -29.52% |
| 2014-12-31 | -38.67% |
| 2013-12-31 | -68.82% |
| 2012-12-31 | -264.34% |
| 2011-12-31 | -298.07% |
| 2010-12-31 | 0.00% |
